The General Hospital Corporation

The Brigham and Women's Hospital, Inc.

University of California

Randall T Peterson

Gregory D Cuny

Kenneth D Bloch

Paul B Yu

Charles C Hong

You Wang

David Kokel

Mark C Fishman

Gerry R Boss

Sari Mahon

Yan Liu

Calum A Macrae

David J Milan

C Geoffrey Burns

Travis Peterson

Andrew J Rennekamp

Robert Gerszten

Anjali Nath

Matt Brenner

Peter J Schlueter

Baohui Zheng

Calum MacRae

Chung Yan J Cheung

Aarti Asnani

The present application provides, inter alia, a compound of Formula (I): or a pharmaceutically acceptable salt thereof, and methods of use of the compound of Formula (I) for treatment and prevention of cyanide poisoning.

Antidotes to cyanide poisoning

The present application provides tricyclic compounds useful, e.g., in treating or preventing cardiotoxicity and cardiomyopathy in patients undergoing cardiotoxic chemotherapy. Methods of making and using the tricyclic compounds to treat cancer are also described.

Tricyclic compounds as Cyp1 inhibitors

The invention described herein relates generally to neuroactive compounds and compositions for the treatment psychotic disorders, methods for treating psychosis using these neuroactive compounds, and methods for screening for novel neuroactive compounds. Certain aspects are directed to a family of compounds called 'finazines.' Certain aspects are directed to in vivo screening methods using high-through-put behavioral assays in zebrafish.

Neuroactive compounds and methods of using the same

Provided herein are methods of sterilizing fish by contacting an embryonic or juvenile fish with a compound of formula (I). In some embodiments, the compound is primordazine or a derivative thereof.

Germ cell ablation compounds and uses thereof

Embodiments of the technology described herein relate, at least in part, to methods of modulating the activity of a neuron by contacting the neuron with a photo-sensitive TrpA1 agonist and then illuminating the neuron with electromagnetic radiation. Also described herein are photo-sensitive TrpA1 agonists.

Compositions and methods for controlling neuronal excitation

The present invention provides pyridinyl-substituted pyrazolyl pyrimidine small molecule inhibitors of bone morphogenetic protein (BMP) signaling having the structure of formula (I), wherein variables A, B, E, F, X, Y, Z, Ar, L, Rand Rare as defined in the specification. The compounds of the invention are useful in modulating cell growth, differentiation, proliferation, and apoptosis, and thus are useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.

Inhibitors of the BMP signaling pathway

The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.

The invention provides methods of diagnosing diseases and conditions associated with PKC&#x3bb;, methods for identifying compounds that can be used to treat or to prevent such diseases and conditions, and methods of using these compounds to treat or to prevent such diseases and conditions. Also provided in the invention are animal model systems that can be used in screening methods.

Methods for diagnosing and treating diseases and conditions associated with protein kinase C&#x3bb;

The invention includes a zebrafish assay for cardiac response.

Growing community of inventors

Belmont, MA, United States of America

Randall T Peterson